Celtic Biotech

Celtic Biotech is a private, preclinical-stage biotech leveraging natural peptides from snake venom to develop targeted cancer therapies. The company's core platform centers on crotoxin, a neurotoxin with demonstrated selective cytotoxicity against tumor cells, initially targeting non-small cell lung cancer (NSCLC) and associated pain. As a pre-revenue entity, Celtic Biotech's near-term value drivers are the advancement of its lead program, CB-24, into clinical trials and the validation of its unique venom-derived platform. The company operates from Dublin, Ireland, and is positioned to address high-unmet-need oncology indications with a novel mechanism of action.

Platform based on isolating and developing therapeutic peptides from snake venom neurotoxins, specifically crotoxin, for selective induction of apoptosis in cancer cells.

Competes directly with all NSCLC therapies (chemotherapy, immunotherapy, targeted therapy) and supportive pain care. Its novel venom-derived mechanism is a differentiator but unproven, placing it against well-funded companies with advanced clinical assets. It may face competition from other biotecks exploring animal venom/toxin platforms.